论文部分内容阅读
目的探讨草酸艾司西酞普兰对老年良性前列腺增生(BPH)伴抑郁患者的总体临床疗效。方法选取104例老年良性前列腺增生合并抑郁症患者,随机分为研究组和对照组,各52例。对照组患者给予常规改善BPH的药物治疗以改善前列腺增生症状,研究组在此基础上给予草酸艾司西酞普兰治疗。比较两组的国际前列腺症状评分(IPSS)、健康调查简表(SF-36)评分和汉密尔顿抑郁量表(HAMD)的评分变化。结果治疗前两组患者上述量表评分组间无明显差异(P>0.05)。治疗后两组患者的IPSS评分均低于治疗前且研究组患者的IPSS评分低于对照组;治疗后研究组HAMD评分显著低于对照组;两组患者治疗后SF-36评分均升高,且观察组高于对照组,上述差异均有统计学意义(P<0.05)。结论老年良性前列腺增生伴抑郁患者在常规改善BPH药物的基础上给予草酸艾司西酞普兰治疗,能够更好地改善其抑郁症状及前列腺增生症状,并能提高患者生活质量。
Objective To investigate the overall clinical efficacy of escitalopram oxalate in senile patients with benign prostatic hyperplasia (BPH) and depression. Methods 104 cases of elderly patients with benign prostatic hyperplasia and depression were randomly divided into study group and control group, with 52 cases in each group. Patients in the control group were given conventional medical treatment to improve BPH to improve the symptoms of benign prostatic hyperplasia. The study group was given escitalopram oxalate. The scores of International Prostate Symptom Score (IPSS), Health Survey Profile (SF-36) and Hamilton Depression Rating Scale (HAMD) were compared between the two groups. Results Before treatment, there was no significant difference between the two groups (P> 0.05). After treatment, the IPSS scores of the two groups were lower than those before treatment, and the IPSS scores of the study group were lower than those of the control group. After treatment, the HAMD score of the study group was significantly lower than that of the control group. SF-36 scores of both groups were increased after treatment, And the observation group was higher than the control group, the above differences were statistically significant (P <0.05). Conclusions Escitalopram oxalate treatment based on the routine improvement of BPH drugs in elderly patients with benign prostatic hyperplasia and depression can better alleviate the symptoms of depressive symptoms and benign prostatic hyperplasia and improve the quality of life of patients.